Review of Accelerated Cancer Treatment Approvals: A Cross-Sectional Study in China from 2005 to 2021 - Top-Institutions - MDSpire

Review of Accelerated Cancer Treatment Approvals: A Cross-Sectional Study in China from 2005 to 2021

  • By

  • Yun Tian

  • Xingyu Liu

  • Xingchen Liu

  • Xiaoyong Liu

  • Shuchen Hu

  • Xiaodong Liu

  • Caijun Yang

  • Yu Fang

  • February 16, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Cancer Drug Development
    • Regulatory Science

  • #2

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Oncology Research
    • Cancer Therapeutics
    • Regulatory Policy

  • #3

    Fudan University Shanghai Cancer Center
    Fudan University Shanghai Cancer Center

    Shanghai, Shanghai

    Key Differentiators

    • Oncology
    • Cancer Drug Development
    • Chinese Regulatory Science

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Cancer Therapeutics
    • Translational Medicine

  • #5

    Peking University Cancer Hospital & Institute
    Peking University Cancer Hospital & Institute

    Beijing, Beijing

    Key Differentiators

    • Oncology
    • Clinical Trials
    • Regulatory Science in China

Original Source(s)

Review of Accelerated Cancer Treatment Approvals: A Cross-Sectional Study in China from 2005 to 2021

  • by Yun Tian, Xingyu Liu, Xingchen Liu, Xiaoyong Liu, Shuchen Hu, Xiaodong Liu, Caijun Yang, Yu Fang

  • February 16, 2026

Related Content

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry